Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Fibroblast growth factor receptor–beta-Klotho complex (FGFR–β-Klotho complex) is a well-established therapeutic target, particularly in metabolic and endocrine disorders. It is also sometimes referred to as FGFR–KLB complex. The name accurately describes the functional signaling unit, which acts as a heterodimeric co-receptor system for Fibroblast Growth Factors (FGFs). This complex plays a crucial role in signal transduction and is involved in the regulation of various metabolic processes, including glucose and lipid homeostasis. The FGFR component is a tyrosine kinase receptor, while beta-Klotho (KLB) functions as a single-pass transmembrane co-receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fibroblast growth factor receptor–beta-Klotho complex (FGFR–β-Klotho complex).